Close Menu

People in the News

Aug 27, 2020

Lucence: Chao Xie

Singapore-based precision oncology company Lucence has appointed Chao Xie as chief data scientist to develop advanced analytics of ultrasensitive liquid biopsy diagnostics for cancer. Xie previously served as head of data science at AirAsia. He won a US Defense Threat Reduction Agency $1M global competition in 2013 for designing an algorithm to rapidly and accurately identify dangerous viruses and bacteria in gene sequencing data.

Aug 26, 2020

Immunovia: Patrik Dahlen and Mats Grahn

Immunovia appointed Patrik Dahlen as its new CEO starting Nov. 1. Dahlen succeeds Mats Grahn, who has been nominated as a member of Immunovia's board.

Dahlen has served as CEO of several diagnostic companies. As CEO of Dako, he implemented a strategic repositioning of the company as a supplier of cancer diagnostics, which resulted in its acquisition by Agilent Technologies for $2.2 billion. As president of life sciences at Perkin Elmer, he was instrumental in building the company's diagnostics business with a niche focus on diagnostic systems for neonatal and prenatal screening.

Aug 25, 2020

Illumina: Kathryne Reeves

Illumina has announced that Kathryne Reeves will join the firm as chief marketing officer on Sept. 28, 2020, reporting to CEO Francis deSouza.

Reeves brings more than 25 years of marketing and management experience and comes to Illumina from Cardinal Health, where she was senior VP of enterprise marketing and general manager of the medical services global business unit. Prior to that, she held positions at Booz Allen Hamilton, AOL/TimeWarner, Nationwide Insurance, and Scotts Miracle-Gro.

Reeves holds an MBA from Harvard Business School.

Aug 24, 2020

AusDiagnostics: Scott Gilroy

AusDiagnostics appointed Scott Gilroy as its new CEO, effective Aug. 24. Gilroy was previously chief operations officer at the company and will take over from Keith Stanley, who will serve as managing director. Gilroy has served in many positions at Malvern Panalytical, including as the general manager for the Australia/New Zealand and Oceania division, regional head of sales and marketing for Asia Pacific, and national sales and marketing manager. 

Aug 21, 2020

Qiagen: Lawrence Rosen

Qiagen has appointed Lawrence Rosen as the chairman of the firm's supervisory board. He will replace Håkan Björklund, who will step down as chairman and as a member of Qiagen's supervisory board. 

Rosen currently has served as a member of Qiagen's supervisory board since 2013. He also serves on the supervisory board of German firm Lanxess. Rosen previously served as a member of the board of management and CFO at Deutsche Post DHL Group until 2016. Prior to that, he held the role of CFO of Fresenius Medical Care from 2003 to 2009. Prior to Fresenius Medical Care, Rosen was senior VP and treasurer for Aventis. Between 1984 and 2000, he held various positions at Avenis predecessor companies Hoechst and American Hoechst/Hoechst Celanese. 

Aug 18, 2020

Becton Dickinson: Kristen Stewart

Becton Dickinson has appointed Kristen Stewart to the newly created position of Senior Vice President of Strategy and Investor Relations, reporting to BD's CFO Chris Reidy. Stewart will work with the BD executive team beginning Aug. 31 to drive shareholder value and to deliver and communicate the company's long-term growth strategy, BD said in a statement. Stewart has worked with investment banks for nearly two decades as a healthcare analyst specializing in medical technology, most recently leading the medical technology research division at Barclays Capital.

Aug 18, 2020

Alveo Technologies: Julianne Averill

Infectious disease diagnostic firm Alveo Technologies recently announced the appointment of Julianne Averill as CFO. She will be responsible for leading all financial operations and implementing strategies to accelerate Alveo's growth, the company said in a statement. Averill has 18 years of leadership experience and most recently served as VP of Finance for BlackThorn Therapeutics. Before that, she held leadership positions at Manifest MedEx and Starwood Waypoint Residential Trust and served as an audit manager at Deloitte. Averill has also participated in or led strategic financing and M&A initiatives totaling more than $2 billion. 

Aug 18, 2020

SQI Diagnostics: Robert Chioini

SQI Diagnostics has appointed Robert Chioini its CEO and a company director, effective Aug. 17. Chioini funded Rockwell Medical and served as its chairman and CEO from 1995 to 2018. He has more than 30 years of operational and business development experience in the medical industry. Eric Brouwer, who had been SQI's interim CEO, will continue as CSO and a director at the company.

Aug 18, 2020

Bionano Genomics: Alka Chaubey

Bionano Genomics has appointed Alka Chaubey as its first chief medical officer, effective Aug. 31, 2020.

Chaubey, a cytogeneticist, will be responsible for driving adoption of the firm's Saphyr optical genome mapping platform for use in clinical applications.

She brings nearly 20 years of scientific and clinical experience and has developed and validated clinical tests, including US Food and Drug Administration-cleared whole-genome cyotgenetic tests. She comes to Bionano from PerkinElmer, where she is head of the cytogenomics. She is also an adjunct assistant professor of pathology at the Medical College of Georgia at Augusta University and is scientific director of the Georgia Esoteric and Molecular Laboratory and the Augusta University Medical Center cytogenetics laboratory. Before coming to PerkinElmer, she directed the Greenwood Genetic Center's cytogenomics laboratory.

Chaubey holds a doctorate in biochemistry and molecular biology from India's Guru Nanak Dev University.

Aug 14, 2020

Pictor: Thomas Schlumpberger

New Zealand-based biotech firm Pictor has appointed Thomas Schlumpberger its CEO where he will be responsible for introducing the company's technology into the US and European markets. He has more than 20 years of experience in the life sciences industry and has held senior executive positions at Anixa; Invitae; Affymetrix, now part of Thermo Fisher Scientific; Inivata; and Singulex. Pictor recently received a NZ$500,000 grant from the Ministry of Business, Innovation, and Employment COVID-19 Innovation Acceleration Fund to develop a test for the detection of SARS-CoV-2 in less than an hour. 

Aug 13, 2020

Myriad Genetics: Paul Diaz

Myriad Genetics has appointed Paul Diaz as its new president and CEO, effective Aug. 13, 2020. Diaz, who will also serve on Myriad's board of directors, will take over from Bryan Riggsbee, who has been serving as the company's interim president and CEO, and CFO after Mark Capone's resignation from that post in February. Diaz served as president, CEO, and in various other roles at Kindred Healthcare, a provider of post-acute healthcare services, for more than a decade. He was also a partner at the private equity firm Cressey & Company LP, and has served as an executive and board member at multiple public and private companies. He is currently on the board of DaVita and a member of the board of trustees of Johns Hopkins Medicine. 

Aug 07, 2020

Tangen Biosciences: Vance Kershner, Alan Levin

Tangen Biosciences has appointed Vance Kershner and Alan Levin to its board of directors in conjunction with a $12.2 million Series B preferred stock financing. Kershner is founder, president, and CEO of LabWare, which develops and implements software for automating laboratory operations. Levin previously served as president and CEO of drugstore chain Happy Harry's, which merged with the Walgreen Company in 2006. Levin also previously served as the Director of the Delaware Economic Development Office.

Aug 05, 2020

Integrity Laboratories: Maria Cekanova

Integrity Laboratories has appointed Maria Cekanova CSO. She was previously director of translational research laboratory and research associate professor of oncology in the department of small animal clinical sciences at the University of Tennessee. Integrity recently received Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 Assay.

Aug 04, 2020

Todos Medical: Jorge Leon

Todos Medical has appointed Jorge Leon as consulting chief medical and scientific officer for infectious disease and oncology, on a part-time basis. 

In the early 1990s, he played a role in establishing the molecular diagnostics laboratories at Quest Diagnostics, Todos said. In 2003, Leon founded Leomics Associates, a consulting firm.

Todos had previously appointed Leon as a medical advisor to assist it with clinical development, regulatory strategy, and fundraising.

Jul 31, 2020

Talis Biomedical: Roger Moody, Kim Popovits, Walter Koch

Talis Biomedical has named Roger Moody as CFO, while Kim Popovits has joined the company's board and Walter Koch has joined its scientific advisory board.

Moody was formerly CFO of Clinical Genomics. He previously was chief executive and COO at Glysure and CFO of Nanosphere and Medsn. Popovits is the former chairman of the board, president, and CEO of Genomic Health, which was acquired by Exact Sciences. She also held several management positions at Genentech, now part of Roche. Koch was at Roche Molecular Systems where he held several leadership roles, including vice president and head of global research. Prior to that, he was at the US Food and Drug Administration.

Jul 29, 2020

Agendia: Brian Dow

Agendia has appointed Brian Dow as CFO. Prior to this position, he served as senior VP and CFO of Pulse Biosciences, where he was responsible for executing the company's early-stage IPO and subsequent follow-on offerings. Before that, he was CFO at Progyny, and prior to that, he was VP and principal accounting officer at Pacific Biosciences. Previously, he also worked for Ernst & Young. Dow holds a bachelor's degree from Georgia Institute of Technology.

Jul 28, 2020

Aegea Biotechnologies: George Maltzeos

Aegea Biotechnologies said that it has hired George Maltzeos as chief engineer to help expedite the development of the company's point-of-care lateral flow molecular SARS-CoV-2 test being developed in collaboration with Tauriga Sciences. Maltzeos previously served as director of the California Institute of Technology Global Health Initiative where he helped secure $4.5 million in funding from the Bill & Melinda Gates Foundation to develop point-of-care clinical diagnostics for developing countries. He also previously founded and served as chief engineer for Helixis, which was acquired by Illumina in 2010. Maltzeos holds a PhD in electrical engineering from CalTech and a BS from Columbia University.

Jul 28, 2020

Clinical Genomics: Michael Paris, Zivjena Vucetic, Edward Rosen

Clinical Genomics has appointed Michael Paris as chief operating officer, Zivjena Vucetic as senior VP, medical, and Edward Rosen as chief strategy and commercial officer.

Paris most recently served as COO and senior VP, operations and technology development, at Origin. Prior to Origin, he served in several positions at Bioconnect Systems, Orthovita, and Rex Medical. 

Before Clinical Genomics, Vucetic served as medical director at Ortho-Clinical Diagnostics. Prior to that, she held multiple scientific and medical roles at Fujirebio Diagnostics. 

Rosen most recently served as an executive in residence at Columbia University. Prior to Columbia, he held several research roles at Johnson & Johnson. 

Jul 28, 2020

Meridian Bioscience: Anthony Bihl

Meridian Bioscience announced the appointment of Anthony Bihl to its board of directors, effective immediately. Bihl retired in April as CEO of Bioventus and was previously the CEO of American Medical Systems and CEO of Siemens Medical Solutions Diagnostics. He has also served in senior executive roles at Bayer Healthcare's diagnostics division and in multiple operations and finance roles at Dupont.

Jul 27, 2020

Veracyte: Jens Holstein, James Erlinger

Veracyte has appointed Jens Holstein to its board of directors and James Erlinger as executive VP, general counsel, and secretary.

Holstein was appointed as CFO of MorphoSys in 2011. Prior to MorphoSys, he served as regional CFO of the Europe/Middle East region for Fresensius Kabi, a subsidiary of Fresenius. He has also held several other leadership roles within the Fresenius group. 

Erlinger previously served as executive VP, general counsel, and secretary of Iqvia. He spent the balance of his career as a partner of the international law firm of Bryan Cave Leighton Paisner. 

Jul 24, 2020

Cradle Genomics: Tanya Moreno, Sue Gross

Prenatal diagnostics firm Cradle Genomics has appointed Tanya Moreno as VP of development and Sue Gross as chief medical officer.

Moreno has 13 years of experience in diagnostics development and the commercialization of genomic tests. She holds a PhD in molecular genetics and developmental biology from the California Institute of Technology.

Gross joins the company from Sema4, where she was medical director for the reproductive lab and clinical analysis division. Previously, she was chief medical officer at Natera, and before that, professor of obstetrics and gynecology, pediatrics, and genetics at Montefiore Einstein. She is a physician with board certifications in obstetrics and gynecology as well as medical genetics.

Jul 23, 2020

Quotient: Isabelle Buckle, Catherine Larue

Quotient announced the appointment of two new members to its board of directors to replace Sarah O'Connor and Thomas Bologna, who are stepping down. Isabelle Buckle is the executive VP of technology transfer and industrial partnership at the Institut Pasteur in Paris. She was previously the global VP of clinical mass spectrometry at Bruker Daltonics and CEO and chairman of InGen Biosciences. 

Catherine Larue is the director of external affairs at the Integrated Biobank of Luxemburg and formerly served as CEO at the biobank. She previously led a business unit at Bio-Rad Laboratories. Both Buckle and Larue will join the board on Sept. 1. 

Jul 22, 2020

Myriad Genetics: Walter Gilbert, Daniel Skovronsky

Myriad Genetics has expanded its board of directors to 10 members with the election of Daniel Skovronsky, CSO and president of Lilly Research Laboratories at Eli Lilly. Skovronsky will serve on the research and product innovation committee within Myriad’s board. Additionally, Myriad announced that Walter Gilbert, the director and vice chair of the board, will retire from these positions at the firm's annual stockholder meeting in December. Gilbert cofounded Myriad and received a Nobel Prize in chemistry in 1980 for his development of rapid DNA sequencing technology. 

Jul 22, 2020

Biodesix: Jean Franchi, Hany Massarany

Biodesix has appointed Jean Franchi and Hany Massarany to its board of directors. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Massarany has extensive experience in the global diagnostics industry, with expertise in molecular diagnostic testing.

Franchi currently serves as chief financial officer for Replimune Group, a biotechnology company developing oncolytic immuno-gene therapies. She has led operational and financial strategy at several companies in domestic and international markets of various stages and sizes, including 16 years at Genzyme. She holds a bachelor's degree in business administration from Hofstra University.

Massarany served as president and chief executive officer of GenMark Diagnostics from 2011 to 2020. Prior to joining GenMark, he held the role of president at Ventana Medical Systems and head of Roche Tissue Diagnostics. From 1999 to 2009 he was responsible for various global leadership positions with Ventana. He has also held executive management positions with Bayer Diagnostics and Chiron Diagnostics. Massarany earned a bachelor’s degree in microbiology and immunology from Monash University and an MBA from Melbourne University.

Jul 20, 2020

Todos Medical: Priyanka Misra, Elise Brownell

Todos Medical has appointed Priyanka Misra VP of corporate development and Elise Brownell VP of R&D. Misra previously was a senior investment analyst at Feller Advisors. Prior to that, she was at Goldman Sachs Asset Management in the Alternative Investments and Manager Selection group. Brownell started her career at the State University of New York, Stony Brook before moving to Frederick Cancer Research Facility and Bayer Healthcare.

Pages